Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Addiction. 2019 Aug 4;115(2):239–246. doi: 10.1111/add.14735

Table 2.

Outcomes on XR-NTX vs placebo with respect to opioid use.

XR-NTX
n = 126
Placebo
n = 124
Rate Ratio
(95% CI)
Patients with ≥2 consecutive positive UDT results 4.8% (6) 12.9% (16) 0.37 (0.15–0.91)
Dropout immediately preceded by a positive UDT result 3.2% (4) 16.1% (20) 0.20 (0.07–0.56)
Completed the study with no positive or missing UDT results 31.0% (39) 20.2% (25) 1.53 (0.99–2.38)

UDT = urine drug test; XR-NTX = extended-release naltrexone.